NewGenIvf Group receives Nasdaq delisting notice, plans to appeal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 22 2024
0mins
Delisting Notice: NewGenIvf Group received a notice from Nasdaq on November 21, 2024, regarding the potential delisting of its securities due to non-compliance with listing rules.
Appeal Process: The company plans to appeal the delisting decision and has requested a hearing, which will temporarily halt any further actions by Nasdaq until the hearing is completed.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NIVF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NIVF
About NIVF
NewGenIvf Group Limited is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. It specializes in in-vitro fertilization (IVF) treatment and surrogacy and ancillary caring services. Its fertility treatments, such as IVF, intracytoplasmic sperm injection, intrauterine insemination, egg freezing, embryo transfer, gender selection, semen analysis, hysteroscopy, fertility checkups, testicular sperm aspiration and percutaneous epididymal sperm aspiration. Its clinics are in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions. It has acquired cytometry technology and assets including 18 fully constructed cell-sorting and dispensing systems, eight partially constructed units and six patents related to advanced microfluidic systems.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NewGenIVF Appoints Legal Expert to Drive $30 Million Tokenized Bond Issuance
- Strategic Leadership Appointment: NewGenIVF Group has appointed Web3 legal expert Joshua Chu as Senior Counsel to lead the company's inaugural $30 million tokenized bond issuance, expected to be completed in Q1 2026, thereby establishing a foundation for future tokenized financing.
- Market Demand Response: In response to investor interest in tokenized bonds, the company has begun preparations for bond issuances linked to its UAE real estate project, aiming to provide compliant digital asset investment opportunities that enhance capital efficiency and diversify funding sources.
- Balance Sheet Transformation: Through a non-dilutive, debt-style tokenized bond structure, NewGenIVF anticipates increasing total assets by up to $28 million in Q1 2026, driving accelerated growth and optimizing its financial structure.
- Partnership Strengthening: Collaboration with Evident Capital provides NewGenIVF with a comprehensive tokenization and distribution platform, ensuring that the bond issuance meets institutional standards and further solidifying the company's leadership position in the digital asset space.
Continue Reading
NewGenIVF Converts Project to Joint Development, Expected Profit Increases to $123 Million
- Profit Enhancement: NewGenIVF plans to convert the Ras Al Khaimah project structure from a joint venture to a joint development, expecting to increase its pre-tax profit from $67 million to $123 million, demonstrating strong confidence in the project's profitability.
- Increased Financial Flexibility: Under the new structure, NewGenProperty Limited will assume full responsibility for project financing, ensuring a 64% share of net profits, which enhances the company's financial flexibility to accelerate development activities.
- Market Opportunity Capture: With the rapid appreciation of the Ras Al Khaimah real estate market, NewGen plans to raise additional funds to support the project conversion, which is expected to generate significant presale proceeds and reduce external funding needs.
- Legal Compliance Assurance: The conversion option has been confirmed by a leading law firm, ensuring that NewGen has the legal right to execute this conversion, thereby enhancing the transaction's legality and enforceability.
Continue Reading